Mirum Pharmaceuticals, Inc.（MIRM）今日盘中股价大涨5.26%，引起了市场的广泛关注。
消息面上，该公司近期宣布其用于治疗罕见肝病的药物volixibat在一项中期研究中达到了主要目标，这一积极的临床进展增强了市场对公司研发管线的信心。此外，根据LSEG数据，覆盖该公司的全部11位分析师均对其持乐观态度，其中4位给予了"强烈买入"评级，目标价中位数也从一个月前的128美元上调至140美元，显示了机构对其未来前景的看好。
与此同时，公司也完成了总额6亿美元的可转换优先票据的定价工作，并计划将部分募集资金用于赎回2029年到期的部分票据，以优化其债务结构。这一系列的公司动态共同构成了推动股价上涨的重要因素。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.